Inclusion Criteria:

- Signed written informed consent (first and second)

- Chinese with Chinese citizenship

- Male or female subjects ≥18 years of age

- Medically accepted effective contraception if procreative potential exists
(applicable for both male and female subjects until at least 90 days after the last
dose of trial treatment)

- Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum

- First occurrence of metastatic disease (not curatively resectable) KRAS wild-type
status in tumor tissue

- At least one measurable lesion by computer tomography (CT) or magnetic resonance
imaging (MRI) according to RECIST (not in an irradiated area)

- Life expectancy of at least 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at trial entry

- White blood cell count ≥ 3 × 10x9/L with neutrophils ≥ 1.5 × 10x9/L, platelet count ≥
100 × 10x9/L and hemoglobin ≥ 6.21 mmol/L (10 g/dL)

- Total bilirubin ≤ 1.5 × upper limit of reference range

- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of
reference range or ≤ 5 × upper reference range in subjects with liver metastasis

- Serum creatinine ≤ 1.5 × upper limit of reference range

- Recovery from relevant toxicity due to previous treatment before trial entry

Exclusion Criteria:

- Previous chemotherapy for CRC except adjuvant treatment if terminated > 9 months
(oxaliplatin-based chemotherapy) or > 6 months (non-oxaliplatin-based chemotherapy)
before the start of treatment in this trial

- Radiotherapy or surgery (excluding prior diagnostic biopsy) in the 30 days before
trial treatment

- Previous treatment with monoclonal antibody therapy, vascular endothelial growth
factor (VEGF) pathway-targeting therapy, epidermal growth factor receptor (EGFR)
pathway-targeting therapy, or other signal transduction inhibitors

- History of organ allograft, autologous stem cell transplantation, or allogeneic stem
cell transplantation

- Renal replacement therapy

- Intake of any investigational medication within 30 days before trial entry

- Concurrent chronic systemic immune therapy or hormone therapy except physiologic
replacement

- Granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony
stimulating factor (GM-CSF) within 3 weeks of trial entry (these growth factors may
be used during the trial thereafter)

- Other non-permitted concomitant anticancer therapies

- Known brain metastasis and/or leptomeningeal disease. Subjects with neurological
symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis

- Previous malignancy other than CRC in the last 5 years except basal cell cancer of
the skin or preinvasive cancer of the cervix

- Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart
Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy,
uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial
infarction in the last 5 years, or left ventricular ejection fraction below the
institutional range of normal on a baseline multiple gated acquisition scan or
echocardiogram

- Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

- Active clinically serious infections (> grade 2 National Cancer Institute-Common
Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0), including active
tuberculosis

- Known and declared history of human immunodeficiency virus (HIV) infection or chronic
hepatitis B or C

- Peripheral neuropathy > grade 1

- Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family
members who suffer(ed) from such

- Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder,
interstitial pneumonia, or liver failure

- Known hypersensitivity or allergic reactions against any of the components of the
trial treatments

- Pregnancy (absence to be confirmed by serum β-human chorionic gonadotropin test) or
breastfeeding

- Ongoing alcohol or drug abuse

- Presence of a medical or psychological condition that would not permit the subject to
complete the trial or sign informed consent

- Participation in another clinical trial within the past 30 days

- Other significant disease that in the investigator's opinion should exclude the
subject from the trial

- Legal incapacity or limited legal capacity